×
Choose Speciality

EXPLORE!

LOGIN

Emerging Systemic Therapy: JAK Inhibitors

  1068 Views

Dr Yashpal Manchanda, New Delhi    21 January 2019

  • Janus kinase inhibitors also known as jakinibs, inhibit the kinase component of JAKs, thereby preventing them from phosphorylating and stopping the transduction of intercellular signalling.
  • First-generation jakinibs, which include the drugs tofacitinib and ruxolitinib inhibit multiple JAKs.
  • Second-generation jakinibs are still under investigation and more selective target only one JAK isoform, thereby inhibiting a narrower range of cytokines.
  • The dermatological uses of jakinibs include atopic dermatitis, psoriasis and psoriatic arthritis.
  • Several other case reports and preclinical evidence suggest that JAK inhibitors may be useful in the treatment of other inflammatory, autoimmune and malignant skin conditions. These include cutaneous lupus, cutaneous T-cell lymphoma, melanoma, allergic contact dermatitis and lichen planus.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.